ClinicalTrials.gg
RecruitingNCT02284581BIO-METAUpdated Nov 13, 2023

Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

An observational study in Metastatic Breast Cancer, sponsored by Consorzio Oncotech. Recruiting at 35 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by Consorzio Oncotech · Observational

How we know

From the registry’s dates

  • Started Nov 2015; still recruiting 11 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Breast Neoplasms by Consorzio Oncotech — 3 open to participants now, 5 under way, none of them phase 3. Breast Neoplasms · Consorzio Oncotech.

Started
2015
with 3 others
Observational
5 of 16
3 open now
Registered
4th of 16
by date

Among the 16 studies in Breast Neoplasms by Consorzio Oncotech, this one is one of 4 that started in 2015, is one of 5 observational ones, and was the 4th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 16 studies in Breast Neoplasms by Consorzio Oncotech are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Breast Neoplasms by Consorzio Oncotech, or all of them as a file.
02

Study summary

Breast cancer is the most common cancer in many countries: in Italy about 48.000 new breast cancers are diagnosed every year and, despite improvements in diagnosis and therapy, about 13.000 women die every year for this disease . About 6-7% of breast cancer patients are metastatic at diagnosis , while the majority of patients with stage IV has a previous history of breast cancer that has already been treated. According to various prognostic factors (tumor size, lymph nodes involvement, grading, hormone receptors status, HER-2 status), in the worst-case scenario, more than 30% of node-negative breast cancer patients and more than 70% of node-positive patients relapse2.

The evolution of metastatic breast cancer has changed considerably in the last years with the approval of new drugs. In fact, already in 2003 Giordano et al showed that the prognosis of metastatic breast cancer patients was improved significantly from 1970's to 2000 with a median survival of 15 months in the early 1970's compared with 60 months in the last 1990's.

This significant survival gain was obtained with introduction of new drugs as hormonal, chemotherapeutic and biological agents. The greater availability of drugs has led to an increase in number of lines of treatment receiving by metastatic breast cancer patients. However, there are few published data on actual duration of metastatic breast cancer treatments. Moreover, there is no evidence to support a real impact on survival of treatments beyond the second-third line.

Recently, a retrospective analysis of about 199 metastatic breast cancer patients treated with chemotherapy showed that tumor subtype is associated with the duration and number of lines of chemotherapy (for example HER positive versus "triple-negative" patients) .

Read the detailed description

The primary objectives are to evaluate the duration of metastatic breast cancer treatments (chemotherapy, hormonal therapy and biological therapies) according to biological subtype (Luminal A, Luminal B, HER2 positive, triple-negative) and to evaluate the number of lines of metastatic breast cancer treatments according to biological subtype (Luminal A, Luminal B, HER2 positive, triple-negative).

The secondary Objectives are to evaluate overall survival according to duration and to number of lines of metastatic breast cancer treatments and to identify predictive factors of number of lines of treatment as for example age, treatment response, biological subtype, metastatic sites, etc and to identify possible elements of different treatment management between participating sites.

The aim of this retrospective and prospective study is to identify the duration of treatments (chemotherapy, hormonal therapy and biological therapies) according to biological subtype and line of treatment in metastatic breast cancer patients.

An ancillary study will be conducted on part of population (HR+/HER2- patients newly diagnosed for mBC receiving first line CDk4/6 inhibitors).

For the ancillary study, it is expected to enroll at least 400 patients, who will be asked to fill in some questionnaires at the following visits, scheduled as per clinical practice:

  • PROFFIT: baseline, day 1 cycle 3, day 1 cycle 5, every 6 months thereafter;
  • Patient-reported outcomes (PRO): EORTC-QLQ-C30, FACT-B, COST-FACIT at baseline, day 1 cycle 3, day 1 cycle 5, every 6 months thereafter.

The ancillary study could evaluate:

  • the impact of first line CDk4/6 inhibitors on HR+/HER2- metastatic breast cancer patients' financial toxicity
  • retrospectively, the correlation between NLR and outcome in patients with breast cancer and in treatment with a CDk4/6 Inhibitor (as first line vs as second line)
  • the correlation between BMI and outcome in patients with breast cancer and in treatment with a CDk4/6 Inhibitor (as first line vs as second line).
03

Conditions studied

  • Metastatic Breast Cancer

Keywords

  • MBC
  • metastatic
  • breast
  • observational
  • disease management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Italian patients with metastatic breast cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Retrospective cohort All consecutive breast cancers patients treated in the participating site with a therapy (chemotherapy or hormonal therapy with or without biological therapy) from last contact with patient or death which ever event comes first retrospectively back until 1 st of January 2000

Prospective cohort All new consecutive metastatic breast cancers patients will be treated in the participating site with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy)from site activation to June 2023.

For the ancillary study

  • Patients eligible for GIM 14 - BIO-META study
  • HR+ - patients newly diagnosed for mBC receiving CDk4/6 inhibitors as first-line or second-line treatment
  • Written

Exclusion criteria

Exclusion Criteria:

Not consecutive breast cancer patients grouped for a particular biological type (for example: all positive patients).

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
10,000 participants (estimated)
Patient registry
No
Biospecimen retention
None retained

Groups and cohorts

  • Retrospective cohort

    All consecutive metastatic breast cancers patients treated in the participating site with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from last contact with patient or death which ever event comes first retrospectively back until 1st of January 2000.

  • Prospective cohort

    All new consecutive metastatic breast cancers patients will be treated in the participating site with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from site activation to June 2023.

06

What researchers measure

Primary outcomes

  1. Duration and number of lines' treatment

    Time frame: Retrospectively from 2000 up to site activation; prospectively assested up to 32 months

Secondary outcomes

  1. Overall Survival according duration

    Time frame: Retrospectively from 2000 up to site activation; prospectively assested up to 32 months

  2. Overall survival according number of lines

    Time frame: Retrospectively from 2000 up to site activation; prospectively assested up to 32 months

  3. Predictive factors of number of lines

    Time frame: Retrospectively from 2000 up to site activation; prospectively assested up to 32 months

  4. Treatment management

    Time frame: Retrospectively from 2000 up to site activation; prospectively assested up to 32 months

Other outcomes

  1. Impact of first line CDk4/6 inhibitors on HR+/HER2-mBC patients' financial toxicity

    Time frame: 30 months

  2. Correlation between NLR and outcome in patients with breast cancer and in treatment with a CDk4/6 Inhibitor (as first line vs as second line)

    Time frame: 30 months

  3. Correlation between BMI and outcome in patients with breast cancer and in treatment with a CDk4/6 Inhibitor (as first line vs as second line)

    Time frame: 30 months

  4. Differences to the previously cited outcomes according to the type of CDk4/6 inhibitors

    Time frame: 30 months

07

Study locations

26 of 35 sites recruiting
  • Centro di Riferimento Oncologico
    Aviano, 33081, Italy
    Recruiting
    • Fabio Puglisi, MD · Contact
    • Fabio Puglisi, MD · Principal investigator
  • A.O. Consorziale Policlinico di Bari
    Bari, 70124, Italy
    Recruiting
    • Stefania Stucci · Contact
    • Stefania Stucci · Principal investigator
  • A.O.U. Cagliari
    Cagliari, 09122, Italy
    Recruiting
    • Francesco Atzori · Contact
    • Francesco Atzori · Principal investigator
  • Fondazione del Piemonte per l'Oncologia - I.R.C.C.
    Candiolo, 10060, Italy
    Recruiting
    • Filippo Montemurro, MD · Contact
    • Filippo Montemurro, MD · Principal investigator
  • Azienda Ospedaliera Ospedale Sant'Anna
    Como, 22020, Italy
    Recruiting
    • Palma Pugliese, MD · Contact
    • Palma Pugliese, MD · Principal investigator
  • Azienda Ospedaliera S. Croce e Carle
    Cuneo, 12100, Italy
    Recruiting
    • Paola Vanella, MD · Contact
    • Paola Vanella, MD · Principal investigator
  • A.O.U. Sant'Anna
    Ferrara, 44124, Italy
    Recruiting
  • Ospedale 'F. Spaziani'
    Frosinone, 03100, Italy
    Not yet recruiting
    • Angela Vaccaro, MD · Contact
    • Angela Vaccaro, MD · Principal investigator
  • Ospedale Policlinico San Martino IRCCS
    Genova, 16132, Italy
    Recruiting
  • A.O. Ospedale Civile di Legnano
    Legnano, 20025, Italy
    Recruiting
    • Elena Collovà · Contact
    • Elena Collovà · Principal investigator
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.
    Meldola, 47014, Italy
    Not yet recruiting
    • Ugo De Giorgi · Contact
    • Ugo De Giorgi · Principal investigator
  • ASST Fatebenefratelli Sacco - P.O. Fatebenefratelli
    Milano, 20121, Italy
    Recruiting
  • Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda
    Milano, 20122, Italy
    Not yet recruiting
  • A.O.R.N. "A. Cardarelli"
    Napoli, 80131, Italy
    Recruiting
  • Azienda ospedaliero universitaria "Federico II"
    Napoli, 80131, Italy
    Recruiting
    • Grazia Arpino, MD · Contact
    • Grazia Arpino, MD · Principal investigator
  • Istituto Nazionale per lo studio dei Tumori - Fondazione 'Pascale'
    Napoli, 80131, Italy
    Recruiting
    • Michele De Laurentiis, MD · Contact
    • Michele De Laurentiis, MD · Principal investigator
  • Azienda Ospedaliero-Universitaria di Parma
    Parma, 43126, Italy
    Not yet recruiting
    • Antonino Musolino · Contact
    • Antonino Musolino · Principal investigator
  • Fondazione Maugeri IRCCS
    Pavia, 27100, Italy
    Recruiting
  • A.O.U. Pisana
    Pisa, 56126, Italy
    Recruiting
  • IRCCS Arcispedale Santa Maria Nuova
    Reggio Emilia, 42123, Italy
    Not yet recruiting
    • Giancarlo Bisagni, MD · Contact
    • Giancarlo Bisagni, MD · Principal investigator
  • Istituto Regina Elena per lo studio e la cura dei tumori
    Roma, 00144, Italy
    Recruiting
    • Francesco Cognetti, Md · Contact
    • Cognetti Francesco, MD · Principal investigator
  • Policlinico Universitario A. Gemelli- DH Radiochemioterapia
    Roma, 00168, Italy
    Recruiting
  • Policlinico Universitario Agostino Gemelli, IRCSS-Unità Medicina di Precisione in Senologia
    Roma, 00168, Italy
    Recruiting
  • Policlinico Umberto I Università "La Sapienza" di Roma
    Roma, 00185, Italy
    Recruiting
    • Enrico Cortesi · Contact
    • Enrico Cortesi · Principal investigator
  • Azienda Ospedaliera S. Andrea
    Roma, 00189, Italy
    Not yet recruiting
    • Paolo Marchetti · Contact
    • Paolo Marchetti · Principal investigator
  • Ospedale Sandro Pertini
    Roma, 00189, Italy
    Recruiting
  • Asl Roma 1 - Ospedale Santo Spirito
    Roma, 00193, Italy
    Recruiting
  • Istituto Clinico Humanitas
    Rozzano, 20089, Italy
    Recruiting
  • Azienda Ospedaliera S. Andrea
    Sassari, 07100, Italy
    Not yet recruiting
    • Carlo Putzu · Contact
    • Carlo Putzu · Principal investigator
  • Ospedale Civile SS. Annunziata
    Sassari, 07100, Italy
    Recruiting
    • Antonio Pazzola · Contact
    • Antonio Pazzola · Principal investigator
  • Ospedale 'SS. Trinità'
    Sora, 03039, Italy
    Not yet recruiting
    • Angela Vaccaro, MD · Contact
    • Angela Vaccaro, MD · Principal investigator
  • A.O.U. Città della Salute e della Scienza di Torino - Presidio San Lazzaro
    Torino, 10126, Italy
    Not yet recruiting
  • P.O. Martini - ASL TO1
    Torino, 10141, Italy
    Recruiting
  • ASL Alessandria - Ospedale Civile Santi Antonio e Margherita
    Tortona, 15057, Italy
    Recruiting
    • Marco Galliano · Contact
    • Marco Galliano · Principal investigator
  • A.O.U. Santa Maria della Misericordia di Udine
    Udine, 33100, Italy
    Recruiting
08

References and documents

Publications

  • Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v15-9. doi: 10.1093/annonc/mdq160. No abstract available. PubMed 20555067 ↗
  • Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, Wollins DS. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012 May 10;30(14):1715-24. doi: 10.1200/JCO.2012.42.8375. Epub 2012 Apr 3. No abstract available. PubMed 22493340 ↗
  • Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014 Jan;12(1):71-80. doi: 10.6004/jnccn.2014.0008. PubMed 24453294 ↗
  • Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ; Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011 Aug;22(8):1736-47. doi: 10.1093/annonc/mdr304. Epub 2011 Jun 27. PubMed 21709140 ↗
  • Conte B, Fabi A, Poggio F, Blondeaux E, Dellepiane C, D'Alonzo A, Buono G, Arpino G, Magri V, Naso G, Presti D, Mura S, Fontana A, Cognetti F, Molinelli C, Pastorino S, Bighin C, Miglietta L, Boccardo F, Lambertini M, Del Mastro L; Gruppo Italiano Mammella (GIM) study group. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. Clin Breast Cancer. 2020 Apr;20(2):e181-e187. doi: 10.1016/j.clbc.2019.09.001. Epub 2019 Nov 14. PubMed 31735691 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Jun 2023, 91 months.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 91 months is above that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2014
First posted
Nov 6, 2014
StartActual
Nov 2015
Primary completionActual
Jun 2023
CompletionEst.
Dec 2025
Last update
Nov 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02284581
Lead sponsor
Consorzio Oncotech
Responsible party
Sponsor
First posted
Nov 6, 2014
Start date
Nov 2015
Primary completion
Jun 2023
Completion
Dec 2025 (estimated)
Last update
Nov 13, 2023

Study contacts

Claudia Bighin, MD
Contact
claudia.bighin@hsanmartino.it
0105600898
Eva Blondeaux, MD
Contact
eva.blondeaux@hsanmartino.it
Claudia Bighin, MD
principal investigator · IRCCS- Azienda Ospedaliera Universitaria San Martino-IST

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion